Novartis AG (NVS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Novartis AG (NVS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

99.36

0.09 (0.09%)

At close: Jan 14, 2025, 3:59 PM

98.66

-0.70%

Pre-market Jan 15, 2025, 04:19 AM EST

undefined% (undefined)

Bid	98.56
Market Cap	194.39B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	5.73
PE Ratio (ttm)	17.34
Forward PE	n/a
Analyst	Hold

Ask	98.61
Volume	1,582,624
Avg. Volume (20D)	1,181,550
Open	98.75
Previous Close	99.27
Day's Range	98.22 - 99.39
52-Week Range	92.35 - 120.92
Beta	undefined

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops,...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Nov 7, 1996

Employees 76,057

Stock Exchange NYSE

Ticker Symbol NVS

Website https://www.novartis.com

Analyst Forecast

According to 6 analyst ratings, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $120.5, which is an increase of 21.28% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Novartis AG is scheduled to release its earnings on Jan 31, 2025, before market opens.
Analysts project revenue of $12.55B, reflecting a 9.87% YoY growth and earnings per share of 1.8, making a 17.65% increase YoY.

Why Price Moved

2 months ago · Source

-4.41%

Novartis shares are trading lower. The company rep... Unlock content with Pro Subscription

4 months ago · Source

-1.46%

Novartis shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and lowered its price target to $130.

News

18 hours ago · seekingalpha.com

Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Novartis AG (NYSE:NVS ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vo...

20 hours ago · youtube.com

Novartis CEO: We need to get Europe to pay its fair share

Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.

23 hours ago · youtube.com

Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line

CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.

2 days ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

1 day ago · seekingalpha.com

Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential

BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite Bi...

4 days ago · seekingalpha.com

Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025

Novartis experienced a strong bull run in 2024 but saw a 13% pullback post-Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 p...

4 days ago · youtube.com

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.

4 days ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

1 week ago · zacks.com

Why Novartis (NVS) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 weeks ago · zacks.com

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.

2 weeks ago · zacks.com

Here's Why Novartis (NVS) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 weeks ago · reuters.com

Novartis gene therapy helps children with rare muscle disorder in study

Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow.

2 weeks ago · reuters.com

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis...

3 weeks ago · zacks.com

Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term

These five laggards of this year have double-digit upside left in the near term. They are: UBER, NVS, RYAAY, OKTA, BAH.

3 weeks ago · reuters.com

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying...

4 weeks ago · zacks.com

NVS vs. LLY: Which Stock Should Value Investors Buy Now?

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?

4 weeks ago · zacks.com

Are Investors Undervaluing Novartis (NVS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

1 month ago · seekingalpha.com

Novartis: Time To Increase

Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include hig...

1 month ago · zacks.com

The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology are included in this Analyst Blog.

1 month ago · zacks.com

Novartis Announces Positive Results From Late-Stage Study on Fabhalta

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.

Load More News